Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell function. BAFF receptor is a target that has been explored in CLL. Preclinical data indicates that CAR- T cells expressing B-cell activating factor (BAFF) can be another effective strategy to treat refractory CLL. This study aims to explore the efficacy of LMY-920 a BAFF-ligand CAR T cells with depletio

Trial Details

NCT ID

NCT06916767

Phase

PHASE1

Sponsor

Paolo Caimi, MD

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• BAFF CAR-T
• Obinutuzumab
• Cyclophosphamide
• Fludarabine

Locations (sample)

• Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

• Histologically confirmed chronic lymphocytic leukemia (including small lymphocytic lymphoma)
• Relapsed after 2 or more lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
• No evidence of CNS lymphoma.
• Male or female ≥ 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →